P08.43 Bevacizumab discontinuation and bevacizumab re-challenge in glioblastoma patients

BACKGROUND AND OBJECTIVE: . In glioblastoma (GBM) patients who benefit from bevacizumab, it is unknown how long this treatment should be continued and whether it may be safely stopped. The aim of the present study was to describe the outcome of 36 responding GBM patients in whom bevacizumab was disc...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Neuro Oncol
Huvudupphovsmän: Bonnet, C., Cartalat-Carel, S., Thomas, L., Joubert, B., Meyronet, D., D’Hombres, A., Jouanneau, E., Guyotat, J., Honnorat, J., Ducray, F.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2016
Ämnen:
P08 Glioblastom and Anaplastic gliomas
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5782672/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now188.176
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk